Cite
HARVARD Citation
Kizilbash, S. et al. (n.d.). Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor. European journal of cancer. pp. S11-S12. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kizilbash, S. et al. (n.d.). Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor. European journal of cancer. pp. S11-S12. [Online].